Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
Phenylaminopyrimidinamide compounds targeting ULK kinase activity provide a selective and less toxic means to inhibit autophagy in cancer and neurodegenerative diseases, enhancing therapeutic efficacy when combined with other treatments.
JP7593947B2Active Publication Date: 2024-12-03DECIPHERA PHARMACEUTICALS LLC
Patent Information
- Application Number
- JP2021566469
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-07
- Filing Date
- 2020-05-08
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-05-08
Smart Images

Figure 0007593947000001 
Figure 0007593947000002 
Figure 0007593947000003
Abstract
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancer. TIFF2022531801000206.tif73100
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Pyrimidine derivatives, pharmaceutical compositions containing these compounds, uses thereof and methods for their preparation
JP2005509624A
chk-, pdk- and akt-inhibiting pyrimidines, their manufacture and pharmaceutical use
JP2006508997A
Novel ulk1 inhibitors and methods of using them
JP2017526674A
Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009122180A1
